Related Experiment Videos
[Myocardial ultrastructure, energetics and function in chronic adriamycin-induced lesions]
Biulleten' Vsesoiuznogo Kardiologicheskogo Nauchnogo Tsentra AMN SSSR
|January 1, 1988
Summary
Adriamycin treatment causes mosaic lesions in rat heart cells, decreasing phosphocreatine and increasing diastolic stiffness. This suggests impaired cardiac filling due to potential ATP deficiency or calcium handling issues.
Area of Science:
- Cardiovascular Research
- Cellular Biology
- Pharmacology
Background:
- Adriamycin (doxorubicin) is a potent chemotherapy agent with known cardiotoxic effects.
- Understanding the cellular mechanisms of adriamycin-induced cardiotoxicity is crucial for developing protective strategies.
Purpose of the Study:
- To investigate the ultrastructural and functional changes in rat myocardium following adriamycin administration.
- To elucidate the biochemical basis for adriamycin-induced cardiac dysfunction.
Main Methods:
- Ultrastructural analysis of cardiomyocytes in adriamycin-treated rats.
- Biochemical assays for myocardial ATP and phosphocreatine levels.
- Assessment of isolated heart pump function and diastolic stiffness.
Main Results:
- Mosaic lesions observed in cardiomyocytes, with altered sarcomeres and mitochondria.
- Significant decrease in myocardial phosphocreatine (45%) without changes in ATP.
- Reduced cardiac pump function and markedly increased left ventricular diastolic stiffness.
Conclusions:
- Adriamycin cardiotoxicity is characterized by distinct cellular damage and impaired cardiac mechanics.
- Increased diastolic stiffness may result from localized ATP deficiency or impaired calcium handling within myofibrils.